Kisunla® (donanemab-azbt) is the #1 newly prescribed amyloid-targeting treatment for Alzheimer's disease (AD)*
*
Based on IQVIA prescription data for total new-to-brand patient starts in the US from 07/1/2025 to 12/31/2025 as of 02/2026.
Kisunla is FDA-approved for adults with early symptomatic AD, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Kisunla can slow the progression of early symptomatic AD, which presents with memory and thinking issues. While Kisunla cannot reverse or stop existing memory and thinking issues that are due to early symptomatic AD, it can help slow the progression of the disease.
After 18 months in a clinical study, people treated with Kisunla experienced a significant slowing of decline compared with placebo.
Select Safety Information
Kisunla can cause Amyloid-Related Imaging Abnormalities, or “ARIA.” ARIA is a common but serious side effect that does not usually cause any symptoms, but can be serious. ARIA can be fatal. ARIA is most commonly seen as temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the brain and infrequently, larger areas of bleeding in the brain can occur.
Learn more about Kisunla
Receive a one-time text with a link to learn more about Kisunla—including how it works and clinical study results—so you’re ready to talk with your doctor.